ProAmpac Celebrates Trio of Honors at 2024 AmeriStar Awards
5.9.2024 18:45:00 EEST | Business Wire | Press release
ProAmpac, a leader in flexible packaging and material science, is thrilled to announce its recognition at the 2024 AmeriStar Awards, securing two wins in the Sustainable Packaging category and contributing to a third recognition for an innovative e-commerce solution. The accolades showcase ProAmpac's dedication to sustainability and innovation with the RAP Sandwich Wedge for Sammi's; ProActive Recyclable RP-1000 Paper Series for Marks & Spencer's organic potatoes; and the insulated paper bag known as ProActive Recyclable FiberCool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905477309/en/
Sammi's RAP Sandwich Wedge (Photo: Business Wire)
"The recognition by AmeriStar reflects our relentless pursuit of innovative and sustainable packaging solutions," said Chad Murdock, president of the fiber division at ProAmpac. "We're honored to have our efforts acknowledged, especially as we continue to advance in areas like the fiberization of packaging that contribute to a more circular economy."
Developed for Sammi’s grab-and-go sandwiches, the high-barrier RAP Sandwich Wedge, with a premium shelf appearance, utilizes a fiber-based carton board with a transparent window. This innovative solution employs modified atmosphere packaging, optimizing product preservation and visibility while maintaining very low oxygen levels for extended shelf life and decreased food waste.
Designed for Marks & Spencer’s organic potatoes, ProAmpac’s second award-winning innovation, the ProActive Recyclable® RP-1000 Paper Series, offers superior robustness and a premium natural look for packing organic potatoes. This fully recyclable packaging has premium sealant technology for running at rate on high-speed form-fill-seal equipment and is curbside recyclable in the UK, while also being FSC-certified for responsible sourcing.
"Our technical team is at the forefront of fiber packaging innovation across diverse markets," said Lynsey Maddison, director of product development at ProAmpac. "We are committed to advancing these technologies to help our customers achieve more sustainable packaging solutions. As we continue to explore new applications and improvements, our goal remains to drive impactful, eco-friendly advancements in the industry.”
In addition to these two awards, ProAmpac contributed to a win in the Packaging that Saves Food category with the ProActive Recyclable FiberCool, an insulated paper bag for e-commerce delivery. This fiber-based, curbside-recyclable solution replaces a bulky traditional multi-package system, reducing packaging weight and drastically enhancing thermal retention. “Our work on FiberCool exemplifies how we can innovate to meet the growing demand for sustainable packaging without compromising on performance,” said Ray Recchia, global innovation manager at ProAmpac. “By improving thermal insulation, we help reduce food spoilage and waste, giving customers more flexibility with their groceries after delivery,” adds Recchia.
As ProAmpac continues to innovate, it remains dedicated to enhancing sustainability and product performance. For more information on ProAmpac’s award-winning packaging solutions, visit ProAmpac.com or contact Marketing@ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by five core values that are the basis for our success: Integrity, Intensity, Innovation, Involvement and Impact. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products and services sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905477309/en/
Contacts
Whitney Miles
ProAmpac
(617) 721-7040
Whitney.Miles@ProAmpac.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom